BackBonus Biogroup Overview

Bonus Biogroup Accounts Payable

Track Bonus Biogroup's accounts payable ($4.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$4.42M
↑ 247.60% YoYΔ $3.15M vs prior year quarter

Peer trimmed avg / median

Loading

Bonus Biogroup Accounts Payable History

Loading

Bonus Biogroup vs. peers: Accounts Payable Comparison

Loading

Bonus Biogroup Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bonus Biogroup (BBIXF) FAQ

Bonus Biogroup posts a accounts payable of $4.4M as of June 2026. That compares with $1.3M in the prior-year period — up 247.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Bonus Biogroup's accounts payable was $1.3M. The latest reading is $4.4M — a 247.6% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of Bonus Biogroup's financial statement story. At $4.4M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BBIXF's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Bonus Biogroup's other metric pages and overview cover the third.

Judging Bonus Biogroup against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in accounts payable easier to interpret. Start with $4.4M here, then scan peer and history charts to see if the gap is persistent.

Questions & Answers